← Leaderboards
Stephen J Russell
Mayo Clinic Coll Of Medicine, Rochester
$9,318,537
Attributed
$11,743,916
Total exposure
9
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2005–19$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$19,895,408 · 10
By mechanism
R01$9,312,876 · 5
P01$8,805,647 · 2
R44$1,613,364 · 2
R43$163,521 · 1
Top collaborators
- Autumn Schulze6 shared
- Angela Dispenzieri3 shared
- Patrycja Lech1 shared
- Kah-Whye Peng1 shared
- Jian Qiao1 shared
- Lukkana Suksanpaisan1 shared
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Angela Dispenzieri$3,292,004
- Donald J. Tindall$5,698,348
- John C. Morris$669,795
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoMonitorMultiple MyelomaCellsDoseVirusTumorToxic EffectOncolyticClinical TrialsInfectionGrantMeasles VirusImmuneGenomeAntibodiesMediatingNeoplastic CellMeaslesMalignant NeoplasmsCell KillingBaseSiteFuture
Grant awards (39)
Mengovirus Replicon for Enhanced Oncolytic Virotherapy$352,802
R01 · FY2019 · CA · contact PI
Mengovirus Replicon for Enhanced Oncolytic Virotherapy$66,165
R01 · FY2019 · CA · contact PI
Phase 2: NIS proteins with altered anion specificity$733,941
R44 · FY2018 · TR
Mengovirus Replicon for Enhanced Oncolytic Virotherapy$363,713
R01 · FY2018 · CA · contact PI
Mengovirus Replicon for Enhanced Oncolytic Virotherapy$68,211
R01 · FY2018 · CA · contact PI
Phase 2: NIS proteins with altered anion specificity$731,514
R44 · FY2017 · TR
Mengovirus Replicon for Enhanced Oncolytic Virotherapy$363,713
R01 · FY2017 · CA · contact PI
Mengovirus Replicon for Enhanced Oncolytic Virotherapy$363,713
R01 · FY2016 · CA · contact PI
Measles Virotherapy for Multiple Myeloma$498,645
R01 · FY2014 · CA · contact PI
NIS PROTEINS WITH ALTERED ANION SPECIFICITY$163,521
R43 · FY2014 · TR
Measles Virotherapy for Multiple Myeloma$482,471
R01 · FY2013 · CA · contact PI
Measles Virotherapy for Multiple Myeloma$514,441
R01 · FY2012 · CA · contact PI
Antibody Neutralization of Therapeutic Viruses$488,632
R01 · FY2012 · CA · contact PI
Radiovirotherapy for Multiple Myeloma$318,489
R01 · FY2012 · CA · contact PI
Antibody Neutralization of Therapeutic Viruses$490,836
R01 · FY2011 · CA · contact PI
Radiovirotherapy for Multiple Myeloma$318,489
R01 · FY2011 · CA · contact PI
Antibody Neutralization of Therapeutic Viruses$508,118
R01 · FY2010 · CA · contact PI
Radiovirotherapy for Multiple Myeloma$328,339
R01 · FY2010 · CA · contact PI
Virotherapy for Squamous Cell Carcinoma of the Head and Neck$147,909
R44 · FY2010 · CA
Antibody Neutralization of Therapeutic Viruses$500,247
R01 · FY2009 · CA · contact PI
Radiovirotherapy for Multiple Myeloma$328,339
R01 · FY2009 · CA · contact PI
Antibody Neutralization of Therapeutic Viruses$486,003
R01 · FY2008 · CA · contact PI
Radiovirotherapy for Multiple Myeloma$328,339
R01 · FY2008 · CA · contact PI
Radiovirotherapy for Multiple Myeloma$308,016
R01 · FY2007 · CA · contact PI
Radiovirotherapy for Multiple Myeloma$317,216
R01 · FY2006 · CA · contact PI
Gene Therapy for Vaso-occlusive Disorders$1,735,581
P01 · FY2005 · HL
Monitoring expression of cell associated transgenes /vector core$347,116
P01 · FY2005 · HL
Radiovirotherapy for Multiple Myeloma$324,850
R01 · FY2005 · CA
Gene Therapy for Vaso-occlusive Disorders$1,698,172
P01 · FY2004 · HL
Radiovirotherapy for Multiple Myeloma$324,850
R01 · FY2004 · CA
Gene Therapy for Vaso-occlusive Disorders$1,667,399
P01 · FY2003 · HL
Radiovirotherapy for Multiple Myeloma$324,850
R01 · FY2003 · CA
Gene Therapy for Vaso-occlusive Disorders$1,535,197
P01 · FY2002 · HL
Monitoring expression of cell associated transgenes /vector core$307,039
P01 · FY2002 · HL
TARGETING ANGIOGENESIS WITH PROTEASE ACTIVATABLE VECTORS$186,241
R01 · FY2002 · CA
Gene Therapy for Vaso-occlusive Disorders$1,515,143
P01 · FY2001 · HL
TARGETING ANGIOGENESIS WITH PROTEASE ACTIVATABLE VECTORS$181,347
R01 · FY2001 · CA
Monitoring expression of cell associated transgenes /vector core$0
P01 · FY2001 · HL
TARGETING ANGIOGENESIS WITH PROTEASE ACTIVATABLE VECTORS$175,801
R01 · FY2000 · CA